Bio-Rad Laboratories (BIO) vs EyePoint (EYPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bio-Rad Laboratories (BIO) has outperformed EyePoint (EYPT) over the past year, gaining 24.1% versus a loss of 74.9%. Over five years, BIO leads with a -49.0% price change compared with -71.0% for EYPT. Bio-Rad Laboratories is the larger company by market cap ($9.84 billion vs $278.4 million), about 35.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | EYPT |
|---|---|---|
| Share price | $367.92 | $3.32 |
| Market cap | $9.84B | $278.35M |
| 1-day change | -0.25% | +4.73% |
| YTD return | +21.43% | -81.83% |
| 1-year return | +24.08% | -74.94% |
| 5-year return | -49.00% | -70.98% |
| P/E ratio (TTM) | 46.63 | — |
| Forward P/E | 37.10 | — |
| EPS (TTM) | $7.89 | $-3.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | — |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $396.23 | $19.11 |
| 52-week low | $236.73 | $3.05 |
| Distance from 52-week high | -7.14% | -82.63% |
| Analyst consensus | hold | none |
| Avg. price target upside | -10.76% | +680.42% |
| Average volume | 276.93K | 3.93M |
| Shares outstanding | 21.68M | 83.84M |
| Employees | 7,450 | 214 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 35.3 times larger than EyePoint by market value ($9.84B vs $278.35M).
- BIO has outperformed EYPT by 99.0 percentage points over the past year.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
BIO vs EYPT FAQ
Which is bigger, Bio-Rad Laboratories or EyePoint?
Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.84B compared with $278.35M for EyePoint (EYPT).
Which stock has performed better over the past year, BIO or EYPT?
BIO returned +24.08% over the past 12 months, compared with -74.94% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and EyePoint in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.